GlaxoSmithKline is planning to sell more than one-third of its 92-acre R&D site in Stevenage, U.K. The proposed sale, which comes amid criticism of GSK’s historically low R&D investment, is part of a plan to turn part of the site into a life science campus. The new campus could deliver 100,000 square meters of new floor space. Source: Fierce Biotech 16/7/2021